You are here

News

subscribe

The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.

10 July 2019

Combining CRISPR gene editing and slow-release antiretroviral treatment to cure HIV

Two out of seven mice who received novel treatment and gene editing technology have had HIV eliminated from their bodies, reveals a ground-breaking study.

16 February 2017

Strong trial results and high resistance barrier for integrase inhibitor treatment put Gilead on path to new HIV drug

Drug trial results for new integrase inhibitor show promising viral suppression rates.

27 January 2017

Discovery of chemical messages between viruses could provide new way to induce HIV latency

One of the first studies into viral communication shows that viruses that infect bacteria (phages) leave chemical messages for each other which help them decide whether to kill or linger. Disrupting these messages could provide a new way to control HIV.

29 November 2016

Early-stage HIV vaccine trial starts in South Africa

New HIV vaccine trial builds on success of 2009 Thai trial that showed 31.2% effectiveness in preventing HIV.

13 November 2016

Treating fungal infections could prevent 1 million AIDS-related deaths by 2020

Over 300,000 AIDS-related deaths each year could be prevented through better diagnosis and treatment of fungal infections

10 November 2016

Promising new device can detect viral load in under 30 minutes

Viral load testing could become more accessible to millions of people living with HIV in sub-Saharan Africa thanks to a new USB testing stick.

30 September 2016

10% of children living with HIV don’t develop AIDS because immune system ignores HIV

The natural ability of some children's immune systems to hold off attacking HIV, thus stopping diseases progression, may provide clues for future treatment.

29 January 2016

Antiretroviral injection gives viral suppression for 17 months

A once-a-week injection that can offer ‘complete viral-load suppression’ for up to 17 months, could be available from 2017 according to Pharmaceutical company CytoDyn Inc. following a trial of 23 patients.